ArticleJournal of asthma and allergy2026
Real-World Impact of Tezepelumab on Asthma Exacerbations, Healthcare Resource Utilization, and Costs in US Patients with Severe Asthma: CROSSROADS-1.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Asthma affects 26 million individuals in the US, with severe cases driving high healthcare use and costs. Tezspire Methods: This retrospective cohort study used IQVIA's PharMetrics Plus claims database linked with Prognos and Quest data (12/17/2020 - 5/31/2024). Patients aged ≥12 years with severe asthma were included if they had continuous 12-month pre- and post-index medical and pharmacy enrollment, and ≥10 tezepelumab claims during 12-month follow-up. The index date was the first tezepelumab claim. Outcomes were compared pre- and post-index and included annualized asthma exacerbation rate (AAER), exacerbation-related healthcare resource utilization (HCRU), and costs. Subgroup analyses were conducted by prior biologic use, blood eosinophil count (BEC), serum IgE, and comorbidities. Results: Among 337 patients (mean age: 50.8 years; 78.0% female), 44.8% were biologic-naive and 55.2% were biologic-experienced. AAER decreased by 49.1% (95% CI: 43.5% to 54.2%; p<0.0001) following tezepelumab initiation, with greater reductions among biologic-naïve patients (55.7% [95% CI: 47.6% to 62.6%]; p<0.0001) and those with high pre-tezepelumab BEC (87.1% [95% CI: 63.5% to 95.5%] for ≥300 cells/µL; p<0.0001). Exacerbation-related healthcare use decreased, with mean inpatient, ED, and outpatient visits per patient declining from 0.14, 0.67, and 3.23 in the pre-index to 0.05, 0.37, and 1.63 in the post-index, respectively (p<0.0001 for all). Associated mean costs per patient were reduced: inpatient from $2,171 to $551 (p=0.0003), ED from $755 to $356 (p=0.0002), and outpatient from $933 to $477 (p<0.0001). Conclusion: Findings from this observational, retrospective analysis show substantial reductions in AAER, exacerbation-related HCRU and costs among patients treated with tezepelumab, with greater improvements observed among patients who were biologic-naive or with high BEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.